Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Other Non-Current Liabilities (2016 - 2025)

Haemonetics has reported Other Non-Current Liabilities over the past 16 years, most recently at $63.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 29.3% year-over-year to $63.6 million; the TTM value through Dec 2025 reached $63.6 million, down 29.3%, while the annual FY2025 figure was $68.2 million, 9.12% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $63.6 million at Haemonetics, down from $66.1 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $100.3 million in Q2 2021 and troughed at $63.6 million in Q4 2025.
  • A 5-year average of $79.6 million and a median of $77.2 million in 2022 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: grew 28.71% in 2024 and later dropped 29.3% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $91.9 million in 2021, then dropped by 14.85% to $78.2 million in 2022, then decreased by 2.51% to $76.3 million in 2023, then increased by 17.97% to $90.0 million in 2024, then dropped by 29.3% to $63.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for HAE at $63.6 million in Q4 2025, $66.1 million in Q3 2025, and $68.1 million in Q2 2025.